BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Primary completion date changed from estimate of Feb 2027 to Oct 6, 2026
    • Interventions: Cyclophosphamide (Drug), EGFRt/BCMA-41BBz CAR T cell (Biological), Lenalidomide. (Drug) to Cyclophosphamide (Drug), EGFRt/BCMA-41BBz CAR T cell (Biological), Lenalidomide. (Drug)
    • Eligibility criteria expanded, about 26 words
    • Publications: details revised at 1 of 1 entry
  2. Primary and study completion dates: Feb 2026 to Feb 2027v18
  3. Re-verified, no change to tracked fieldsv17
  4. Primary and study completion dates: Feb 2025 to Feb 2026v16
  5. Primary and study completion dates: Feb 2024 to Feb 2025v15
Show 13 earlier versionsHide 13 earlier versions
  1. Primary and study completion dates: Feb 2023 to Feb 2024v14
  2. Primary and study completion dates: Feb 2022 to Feb 2023v13
  3. Re-verified, no change to tracked fieldsv12
  4. Primary and study completion dates: Feb 2021 to Feb 2022v11
  5. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 36 to confirmed 20
    • Site details revised
    v10
  6. Primary and study completion dates: Feb 2020 to Feb 2021v9
  7. 2 versions Re-verified since Sep 7, 2018, no change to tracked fieldsv7-v8
  8. Study title shortened, about 5 wordsv6
  9. Enrollment target: 24 to 36v5 Show 4 more changesShow less
    • Primary and study completion dates: Feb 2019 to Feb 2020
    • Interventions: Cyclophosphamide (Drug), EGFRt/BCMA-41BBz CAR T cell (Biological) to Cyclophosphamide (Drug), EGFRt/BCMA-41BBz CAR T cell (Biological), Lenalidomide. (Drug)
    • Eligibility criteria expanded, about 69 words
    • Study title expanded, about 9 words
  10. Re-verified, no change to tracked fieldsv4
  11. Eligibility criteria expanded, about 1 wordv3
  12. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this phase I clinical trial is to test the safety of these CAR T cells in patients with myeloma. There are two parts of this study. Part 1 of the study consists of screening for BCMA, Lenalidomide assignment and cell collection. Part 2 of the study is treatment with modified CAR T cells.
Trial Details
NCT Number NCT03070327
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov